Hemostasis

1. THE 2-MINUTE PHYSIOLOGY (Rapid Pathophysiology)

• Primary Hemostasis (Platelet Plug): This is the immediate response to endothelial injury involving platelet adhesion, activation, and aggregation. Defects here (like Von Willebrand Disease or Uremic Platelet Dysfunction) lead to mucocutaneous bleeding (petechiae, epistaxis, GI bleeding).
• Uremic Platelet Dysfunction (Outside Information): Urea toxins disrupt the von Willebrand Factor (vWF) and glycoprotein IIb/IIIa receptor interaction, impairing platelet aggregation despite normal platelet counts.
• Secondary Hemostasis (Fibrin Cross-linking): This involves the coagulation cascade generating a stable fibrin clot. It is divided into the Contact Activation (Intrinsic) pathway involving factors XII, XI, IX, and VIII, and the Tissue Factor (Extrinsic) pathway involving factor VII. Both feed into the Common pathway (Factors X, II, and Fibrinogen/I).
• Hemophilias: These are defects of the intrinsic pathway. Hemophilia A is a Factor VIII deficiency, Hemophilia B is a Factor IX deficiency, and Hemophilia C is a Factor XI deficiency. Defects here lead to deep tissue bleeding (hemarthrosis, intramuscular hematomas).
• Acute Traumatic Coagulopathy: Massive hemorrhage drives a lethal triad of coagulopathy, hypothermia, and acidosis. Resuscitation must target restoring factors, preventing fibrinolysis, and maintaining ionized calcium for the cascade to function.

2. THE BEDSIDE ACTION PLAN (Rapid ER Management)

• The xABCDE Approach: Treat the greatest threat to life first. The "x" stands for control of exsanguinating hemorrhage via tiered direct pressure, wound packing, and tourniquet application. A properly applied extremity tourniquet must eliminate the distal pulse.
• Massive Hemorrhage Protocol (MHP) Targets:
• Ratios: Transfuse using a 6:6:1 ratio—6 units PRBCs : 6 units FFP : 1 Plateletpheresis pack.
• Laboratory Targets: Maintain Hb > 7 g/dL, INR < 1.8, Platelets > 50,000 (or > 100,000 for intracranial hemorrhage), and Fibrinogen > 1.5–2.0 g/L.
• The Calcium Imperative: Citrate in banked blood chelates calcium. Administer 1g of Calcium with the first unit of blood, then 1g per 4 units of PRBCs, maintaining an ionized calcium > 1.0–1.2 mmol/L.
• Tranexamic Acid (TXA) Dosing:
• Trauma: 2g IV early (within 1 to 1.5 hours; cutoff is generally 3 hours, though emerging data suggests a 90-minute cutoff). Another accepted dose is 10 mg/kg IV.
• Postpartum Hemorrhage (PPH): 1g IV, then repeat.
• Hemophilia & vWD Management:
• Mild Hemophilia A: Administer DDAVP (if the patient has previously responded to it).
• Mucosal Bleeding: Add an antifibrinolytic (TXA or epsilon-aminocaproic acid [EACA]) in addition to factor replacement.
• Hemarthrosis: Combine factor replacement with RICE (Rest, Immobilization, Cold compresses, Elevation).

3. THE DIAGNOSTIC GRID (Differential Diagnosis & Workup)

• "Can't-Miss" Differentials: Distinguish between isolated platelet disorders (Thrombocytopenia, Heparin-Induced Thrombocytopenia), inherited coagulopathies (Hemophilia, vWD), and consumptive processes like Disseminated Intravascular Coagulation (DIC).
• Prioritized Workup:
• The Standard Panel: PT/INR (Extrinsic/Common pathways), aPTT (Intrinsic/Common pathways), Fibrinogen, and a CBC for platelet count.
• Mixing Studies (Outside Information): Mix patient plasma 50:50 with normal plasma. If the aPTT corrects, it is a factor deficiency (e.g., Hemophilia). If it fails to correct, it is an inhibitor (e.g., autoantibodies).
• Specific Assays: Factor VIII and IX levels, vWF antigen, and Ristocetin cofactor activity (Outside Information).

4. THE VISUAL BOARD (ECG / POCUS / Imaging)

• Clinical Visuals of Bleeding:
• Primary Hemostasis Defects: Petechiae, purpura, mild/minor oral bleeding, and early/mild hemarthrosis.
• Secondary Hemostasis Defects: Significant, tense hemarthrosis, expanding muscle hematomas, and profound delayed bleeding. Look for hematomas that expand with time.
• TEG / ROTEM Interpretation (Outside Information): Rotational thromboelastometry (ROTEM) provides a real-time visual of clot formation and breakdown.
• R-Time (Reaction Time): Represents time to initial clot formation (Factors). If prolonged -> Administer FFP.
• K-Time & Alpha Angle: Represents clot kinetics and fibrinogen activity. If abnormal -> Administer Cryoprecipitate.
• Maximum Amplitude (MA): Represents ultimate clot strength (Platelets). If low -> Administer Platelets.
• LY30 (Lysis at 30 mins): Represents fibrinolysis. If elevated -> Administer TXA.

5. THE SCORING MATRIX (Risk Stratification & Guidelines)

• The ABC Score (Assessment of Blood Consumption): Used to trigger the Massive Hemorrhage Protocol. Trigger the MHP after 3 units of blood are required.
• HAS-BLED Score (Outside Information): Evaluates 1-year major bleeding risk in patients on anticoagulation for atrial fibrillation. Scores ≥ 3 indicate high risk, prompting cautious antithrombotic management and frequent monitoring.
• ISTH DIC Score (Outside Information): Uses Platelet count, D-Dimer/FDPs, prolonged PT, and Fibrinogen levels. A score ≥ 5 is compatible with overt DIC.

6. THE DANGER ZONE (Pitfalls & Critical Actions)

• Critical Action: In massive transfusion, failing to aggressively replace calcium will result in cardiovascular collapse. You must stay ahead by giving 1g Calcium per 4 units PRBCs.
• Deadly Pitfall: Administering TXA for acute Gastrointestinal (GI) bleeding. Literature shows this can cause harm and it should be actively avoided.
• Controversy/Trap: Using TXA in isolated traumatic brain injury. The CRASH-3 trial data is ambiguous; some experts administer it, while others strictly avoid it.
• Critical Action: Always document the neurovascular status of all four limbs after applying hemorrhage control devices like tourniquets, ensuring the distal pulse is definitively eliminated.

7. MCQ MASTERCLASS (Written Exam Tips)

• Buzzwords:
• "Contact activation pathway" = Intrinsic pathway (XII, XI, IX, VIII).
• "Tissue factor pathway" = Extrinsic pathway (VII).
• "Prolonged bleeding after tooth extraction with normal PT/PTT" = suspect von Willebrand Disease (Outside Information).
• Distractor Trap: A question describes a patient with severe hemophilia A presenting with a tense hemarthrosis. A distractor option will be "Administer DDAVP and discharge." Correction: DDAVP is only indicated for mild bleeding in patients with a known previous response. Severe bleeding requires immediate recombinant Factor VIII replacement and RICE.
• Distractor Trap: Administering a 1:1:1 ratio of PRBCs, FFP, and whole platelets. Correction: The correct protocolized ratio is 6 units PRBCs : 6 units FFP : 1 Plateletpheresis pack.

8. THE BOARDROOM SCRIPT (OSCE & Oral Board Tips)

• The xABCDE Opening: "My first priority is the 'x' in the primary survey. I am looking for active, large-volume, compressible external hemorrhage. I will apply tiered direct pressure, pack the wound, and apply a tourniquet until the distal pulse is eliminated.".
• Activating the MHP: "This patient is in hemorrhagic shock and has triggered the ABC score. I am activating the Massive Hemorrhage Protocol. I want 6 units of uncrossmatched PRBCs, 6 units of FFP, and 1 Platelet pack infused rapidly. I am ordering 2 grams of IV TXA and 1 gram of Calcium to be given with the first unit of blood.".
• Hemophilia Escalation: "Given the history of Hemophilia A and mucosal bleeding, I am ordering targeted Factor VIII replacement and an antifibrinolytic like TXA. I am placing ice on the joint and elevating the extremity.".